Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE

Nicholas James, Lazaros Andronis, Ilias Goranitis, Ann Pope, Sarah Pirrie, Darren Barton, Adam Daunton, Duncan McLaren, Lucinda Billingham

Research output: Contribution to conference (unpublished)Poster

Fingerprint

Dive into the research topics of 'Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE'. Together they form a unique fingerprint.

Medicine & Life Sciences